Veloxis Pharmaceuticals A/S

Asahi Kasei Corporation aims to build on the US presence it established and the health care business growth it jumpstarted when it bought Veloxis Pharmaceuticals A/S by paying approximately $1.1bn

Among the US Food and Drug Administration’s enormous workload, one task is consuming much more of its time: determining if products qualify for three-year exclusivity when the sponsor conducts a new c

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca To Study ‘Elite Controller’

In this their first podcast, the Asia-based content team for Scrip and the Pink Sheet take a look at some of the major events shaping the pharma industry in the region over the past few weeks. Joi